Type 2 Diabetes Treatment and Drug Development Study
Da-Yong Lu1, *, Jin-Yu Che1, Nagendra Sastry Yarla2, Hong-Ying Wu1, Ting-Ren Lu1, Bin Xu3, Shu-Yun Wu3, Jian Ding3, Yi Lu4, Hong Zhu5
1 Shanghai University, Shanghai, P. R. China
2 Divisions of Biochemistry and Chemistry, City University of New York School of Medicine, 160 Convent Avenue, New York, NY 10031, USA
3 Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China
4 Shanghai Ocean University, Shanghai, P. R. China
5 College of Pharmaceutical Science, Zhejiang University, Hangzhou, P. R. China
The causality and etio-pathologic risks for patients with Type 2 Diabetes (T2DM) are important areas in modern medicine. Disease complications are largely unpredictable in patients with T2DM. In the future, we welcome therapeutics of both cutting-edge and traditional for anti-diabetic treatments and management with higher efficiency and less cost. Expanding medical knowledge, behavior/life-style notification in healthcare, modern genetic/bioinformatics diagnostic promotion, clinical developments (Traditional Chinese Medicine and personalized medicine) and new drug developments - including candidate drug targets should be implemented in the future. These efforts might be useful avenues for updating anti-diabetic therapeutics globally. This article aims at introducing this information for T2DM treatment boosts.
Keywords: Diabetes Mellitus, Diabetes therapy, Medical education, Type 2 diabetes, Insulin-derivatives, Bee extract, Cardiovascular complication, Hyperglycemia, Traditional Chinese Medicine.
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
* Address correspondence to this author at the Shanghai University, Shanghai, P. R. China; Email: firstname.lastname@example.org